Pandemic H1N1 Influenza Vaccine Quick Reference Guide
QUICK REFERENCE GUIDE FOR SCHOOL-BASED GRADE 9 IMMUNIZATIONS
Tdap Vaccine - Combined diphtheria, tetanus, acellular pertussis (adsorbed) vaccine
Manitoba Eligibility Criteria for Publicly Funded Vaccines: This vaccine is free of charge to students 14-16 years of age, individuals who missed the vaccine in grade 8 or 9 and are born on or after January 1, 1989, and all individuals ≥ 7 years of age who have not been previously immunized with pertussis vaccine.
|Trade Name/ Description |Contents |Supplied |
|BOOSTRIX® |Active Ingredients*: | BOOSTRIX® |
|GlaxoSmithKlineCombined diphtheria, tetanus, |Diphtheria toxoid, tetanus toxoid, 3 purified pertussis antigens. |is supplied as a turbid white |
|acellular pertussis (adsorbed) subunit vaccine for |Inactive Ingredients: |suspension in a single dose vial |
|booster vaccination |Adjuvant: aluminum (adsorbed onto aluminum salts) | |
| |Other ingredients: sodium chloride and water for injection. | |
| | | |
| |The product packaging is NOT declared latex free. | |
|ADACEL ® |Active Ingredients*: | ADACEL® is supplied as a sterile |
|Sanofi Pasteur |Tetanus toxoid, diphtheria toxoid, 5 purified pertussis antigens |uniform, cloudy, white suspension in a |
|Tetanus toxoid, reduced diphtheria toxoid, and |Inactive Ingredients: |vial. |
|acellular pertussis vaccine (adsorbed). |Aluminum Phosphate (adjuvant), 2-phenoxyethanol | |
| |Manufacturing process residuals: Formaldehyde and glutaraldehyde are present in trace amounts. |Shake the vial well until a uniform, |
|Available for individuals that have latex allergies.| |cloudy, suspension results. |
| |The vials are made of Type 1 glass. The container closure system of ADACEL® is free of latex (natural | |
| |rubber). | |
Store refrigerated at 2°C to 8°C. Upon storage, a white deposit and clear supernatant can be observed.
|Age |Dose / Schedule |Route / Needle Gauge /Length |
|Ages four years and older. |One 0.5 mL dose** |IM (deltoid) |
| | |1 – 1 ½ ” |
| | |22-25 G |
Boosters for diphtheria and tetanus are recommended every 10 years.
* The antigen content of this vaccine (including the pertussis content) is lower than in the vaccines used in preschool children.
** There is no evidence of increased risk of severe adverse events for adolescents who receive diphtheria- and tetanus toxoid-containing vaccines at intervals of < 5 years. The pertussis booster (Tdap) should not be delayed for fear of adverse events related to the diphtheria or tetanus toxoid component, regardless of the elapsed time since the previous diphtheria and tetanus toxoid -containing vaccine. NACI Oct 2005
Sources: Product Monographs GlaxoSmithKline (Boostrix) August 15, 2013 Sanofi Pasteur ( Adacel) June 11 2012 & Canadian Immunization Guide Evergreen Ed. @ & &
................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.